|  |  |  |
| --- | --- | --- |
|  | ER+ | ER- |
| Age (median) | 61 | 40 |
| Race |  |  |
| Caucasian | 10 | 7 |
| AA | 6 | 2 |
| Tumor Size |  |  |
| ≤2cm | 4 | 0 |
| >2cm | 10 | 9 |
| TX | 2 | 0 |
| Nodal Status |  |  |
| Negative | 4 | 3 |
| Positive | 8 | 6 |
| NX | 4 | 0 |
| Median Follow-up | 102 months | 89 months |
| Chemotherapy |  |  |
| Yes | 4 | 7 |
| No | 12 | 2 |
| Hormonal Therapy |  |  |
| Yes | 11 | 1 |
| No | 5 | 8 |
|  |  |  |

Supplemental Table 1. Clinical and demographic characteristics.